Zentalis Pharmaceuticals Stock Price

1.63 (2.57%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Zentalis Pharmaceuticals Inc ZNTL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.63 2.57% 65.17 16:00:09
Open Price Low Price High Price Close Price Prev Close
63.73 62.69 65.36 65.17 63.54
Bid Price Ask Price Spread News
52.00 75.00 23.00 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,139 137,794 $ 64.14 $ 8,838,176 - 26.70 - 74.99
Last Trade Time Type Quantity Stock Price Currency
16:00:48 formt 790 $ 65.17 USD


Draw Mode:

Zentalis Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.94B 45.05M 30.59M $ - $ - -3.16 -14.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -178.23k 7.30%

more financials information »

Zentalis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZNTL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week73.5874.3162.6868.58610,808-8.41-11.43%
1 Month62.4174.9961.3268.56326,4852.764.42%
3 Months53.2074.9945.5258.39277,58511.9722.5%
6 Months47.4274.9937.2754.84307,18617.7537.43%
1 Year27.9374.9926.7050.33304,82537.24133.33%
3 Years24.6974.9922.0047.69267,15440.48163.95%
5 Years24.6974.9922.0047.69267,15440.48163.95%

Zentalis Pharmaceuticals Description

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Your Recent History
Zentalis P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.